Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial
Open Access
- 5 July 2021
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 125 (7) , 955-965
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, unpleasant and usually long-lasting side effect of neurotoxic chemotherapeutic agents. This study aimed to investigate the preventive potential of sensorimotor- (SMT) and resistance training (RT) on CIPN. Methods: Patients (N = 170) were randomised to SMT, RT or usual care (UC). Both exercise groups trained 3×/week for a total of 105 min/week during neurotoxic chemotherapy (mean length: 20 weeks). Before and 3 weeks after neurotoxic chemotherapy, CIPN signs/symptoms were assessed via Total Neuropathy Score (TNSr; primary endpoint) and EORTC QLQ-CIPN15 questionnaire. In addition, balance (centre of pressure), muscle strength (isokinetic), quality of life (QoL, EORTC QLQ-C30) and relative chemotherapy dose intensity (RDI) were investigated. The follow-up period covered 6 months after the end of chemotherapy. Results: Intention-to-treat analyses (N = 159) revealed no differences regarding CIPN signs/symptoms. Exploratory per-protocol analyses (minimum training attendance rate 67%; N = 89) indicated that subjectively perceived sensory symptoms in the feet increased less during chemotherapy in the adherent exercisers (pooled group: SMT+RT) than in the UC group (−8.3 points (−16.1 to −0.4); P = 0.039, ES = 1.27). Furthermore, adherent exercisers received a higher RDI (96.6 ± 4.8 vs. 92.2 ± 9.4; P = 0.045), showed a better course of muscular strength (+20.8 Nm (11.2–30.4); P < 0.001, ES = 0.57) and QoL (+12.9 points (3.9–21.8); P = 0.005, ES = 0.64). During follow-up, CIPN signs/symptoms persisted in all groups. Conclusions: This study demonstrates that SMT and/or RT alleviate subjectively perceived sensory CIPN symptoms in the feet and other clinically relevant cancer therapy-related outcomes, if an appropriate training stimulus is achieved. Clinical trial registration: NCT02871284.Keywords
Funding Information
- intramural funding program: Proof of concept trials 3.0, National Center for Tumor Diseases, Heidelberg
This publication has 49 references indexed in Scilit:
- Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IVSupportive Care in Cancer, 2013
- Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 QuestionnaireQuality of Life Research, 2013
- Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patientsAnnals of Oncology, 2011
- Balance Training for Neuromuscular Control and Performance Enhancement: A Systematic ReviewJournal of Athletic Training, 2010
- The Falls Efficacy Scale International (FES-I). A comprehensive longitudinal validation studyAge and Ageing, 2010
- Spinal and supraspinal adaptations associated with balance training and their functional relevanceActa Physiologica, 2008
- Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicityJournal of the Peripheral Nervous System, 2006
- Development and initial validation of the Falls Efficacy Scale-International (FES-I)Age and Ageing, 2005
- The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20European Journal of Cancer, 2005
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993